Kolon TissueGene tumbles on mislabeling revelation for cell therapy Invossa

Kolon TissueGene suspended enrollment in a U.S. Phase III trial of Invossa after finding that the osteoarthritis therapy's TGFB1-expressing component is

Read the full 216 word article

How to gain access

Continue reading with a
two-week free trial.